Immunogenicity of a public neoantigen derived from mutated <i>PIK3CA</i>Smita S. Chandran(Memorial Sloan Kettering Cancer Center), Christopher A. Klebanoff(Memorial Sloan Kettering Cancer Center)bioRxiv (Cold Spring Harbor Laboratory)April 9, 202110.1101/2021.04.08.439061Cited by 3SaveCiteExport RISWatch citationsRelated PapersInhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy|JCI Insight|2017|221Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA|Nature Medicine|2022|126